Anti-tumour effects & tolerability of Faslodex alone or in combination with Arimidex in post menopausal women prior to surgery for primary breast cancer

Study identifier:D6997C00057

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomized, multicentre trial to compare the anti-tumour effects and tolerability of a 500 mg dose of Faslodex (fulvestrant) plus Arimidex (anastrozole) with a 500 mg dose of Faslodex(fulvestrant) alone and with Arimidex(anastrozole) alone, in postmenopausal women prior to surgery for primary breast cancer

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Fulvestrant, Anastrazole

Sex

Female

Actual Enrollment

120

Study type

Interventional

Age

N/A

Date

Study Start Date: 01 Apr 2004
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2008

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria